Why the study?
Does the addition of calusterone to low-dose adriamycin plus cyclophosphamide improve outcomes in women with advanced metastatic breast cancer?
Population
56 women with advanced metastatic breast cancer who had not received prior chemotherapy
Comparison
Low-dose adriamycin plus cyclophosphamide in… vs Low-dose adriamycin plus cyclophosphamide alone
Authors
Loading...
May support chemohormonal therapy in metastatic breast cancer; hypothesis-generating and requires randomized confirmation.
Does the addition of calusterone to low-dose adriamycin plus cyclophosphamide improve outcomes in women with advanced metastatic breast cancer?
The addition of the androgenic steroid calusterone to cytotoxic chemotherapy significantly prolonged remission duration and survival in women with metastatic breast cancer.
Lloyd et al. (1979) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: